By MELINDA J. OVERSTREET for Glasgow News 1 In September 2023, he had been fighting a cold for weeks and weeks. His immune ...

Session ID: 2025-07-04:ba1d8a749c60ce2add2477f5 Player Element ID: vjs_video_3 ...

Shahzad Raza, MD, discusses new data from the phase 2 RedirecTT-1 study of talquetamab with teclistamab for the treatment of patients with relapsed/refractory multiple myeloma and extramedullary ...

Rehan and Parimala, two South Indian cancer survivors, are thriving after Car-T cell therapy at Narayana Health City. Rehan, in remission from lymphoma for 31 months, has regained energy and a normal ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging ...

Darzalex as monotherapy was investigated in two main studies involving multiple myeloma patients whose disease relapsed after, or was refractory to, at least two previous treatments, including a ...

The good news, I guess, is that we have very many different treatment options for relapse refractory multiple myeloma, and some of that is considered in the background of what we do for patients with ...

Multiple myeloma causes lytic or osteolytic lesions, which are areas of damage caused by cancerous plasma cells blocking normal bone growth. While painful, they can be managed. Multiple myeloma is ...